Company: TEM
Filing Date: 2025-02-24
Form Type: 10-K
Source: 0000950170-25-025603
Chunk: 349

Company: Tempus AI, Inc.
Filing Date: 2025-02-24
Form: 10-K
Item: Item 8
Chunk 349
---
 WarrantLiability

        ContingentConsideration

        Balance at December 31, 2022
         
        $
        42,500

        $
        —

        Contingent consideration from acquisitions

        —

        1,175

        Change in fair value of warrant

        (8,000
        )

        —

        Change in fair value of contingent consideration

        —

        (400
        )

        Balance at December 31, 2023
         
        $
        34,500

        $
        775

        Warrant Liability

        Contingent Consideration

        Balance at December 31, 2021
         
        $
        37,800

        $
        8,005

        Change in fair value of warrant liability

        4,700

        —

        Change in fair value of contingent consideration

        —

        (3,701
        )

        Settlement paid in non-voting common shares

        —

        (4,304
        )

        Balance at December 31, 2022
         
        $
        42,500

        $
        —

174

For the year ended December 31, 2024, the Company recognized a loss of $42.4 million in Other income (expense), net due to the change in the fair value of warrant liability determined by Level 3 valuation techniques. For the year ended December 31, 2023, the Company recognized a gain of $0.4 million in Selling, general and administrative expense due to the change in fair value of contingent consideration and gains of $8.0 million due to changes in fair value of the warrant liability determined by Level 3 valuation techniques. For the year ended December 31, 2022, the Company recognized a gain of $3.7 million in selling, general and administrative expense due to the change in fair value of contingent consideration and $4.7 million in other income (expense), net due to the change in the fair value of warrant liability determined by level 3 valuation techniques.Marketable Equity Securities The Company holds marketable equity securities, which are all publicly traded shares of Recursion Pharmaceuticals, Inc. ("Recursion") Class A common stock and Personalis common stock.Recursion shares were received as payment of accounts receivable. During the year ended December 31, 2024, the Company sold 1,725,902 shares of Recursion Class A common stock at a weighted average price of $13